アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

bryant ranch prepack - testosterone (unii: 3xmk78s47o) (testosterone - unii:3xmk78s47o) - testosterone gel, 1.62% is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: - primary hypogonadism (congenital or acquired): testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. these men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [fsh], luteinizing hormone [lh]) above the normal range. - hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone releasing hormone (lhrh) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. these men have low testosterone serum concentrations, but have gonadotropins in the normal or low range. limitations of use: - safety and efficacy of testosterone gel, 1.62% in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established. - safety and efficacy of testosterone gel, 1.62% in males less than 18 years old have not been established [see use in specific populations (8.4)] . - topical testosterone products may have different doses, strengths, or application instructions that may result in different systemic exposure [see indications and usage ( 1 ), and clinical pharmacology (12.3 )]. - testosterone gel, 1.62% is contraindicated in men with carcinoma of the breast or known or suspected carcinoma of the prostate [see warnings and precautions (5.1 ) and adverse reactions (6.1 )]. - testosterone gel, 1.62% is contraindicated in women who are pregnant. testosterone gel, 1.62% can cause virilization of the female fetus when administered to a pregnant woman. pregnant women need to be aware of the potential for transfer of testosterone from men treated with testosterone gel, 1.62%. if a pregnant woman is exposed to testosterone gel, 1.62%, she should be apprised of the potential hazard to the fetus [see warnings and precautions (5.2) and use in specific populations (8.1)] . risk summary testosterone gel, 1.62% is contraindicated pregnant women. testosterone is teratogenic and may cause fetal harm when administered to a pregnanat woman based on data from animal studies and its mechanism of action [see contraindications (4) and clinical pharmacology (12.1)] . exposure of a female fetus to androgens may result in varying degrees of virilization. in animal developmental studies, exposure to testosterone in utero resulted in hormonal and behavioral changes in offspring and structural impairments of reproductive tissues in femail and male offspring. these studies did not meet current standards for nonclinical develpment toxicity studies. data animal data in developmental studies conducted in rats, rabbits, pigs, sheep and rhesus monkeys, pregnant animals received intramuscular injection of testosterone during the period of organogenesis. testosterone treatment at doses that were comparable to those used for testosterone replacement therapy resulted in structural impairments in both female and male offspring. structural impairments observed in females included increased ano-genital distance, phallus development, empty scrotum, no external vagina, intrauterine growth retardation, reduced ovarian reserve, and increased ovarian follicular recruitment. structural impairments seen in male offspring included increased testicular weight, larger seminal tubular lumen diameter, and higher frequency of occluded tubule lumen. increased pituitary weight was seen in both sexes. testosterone exposure in utero also resulted in hormonal and behavioral changes in offspring. hypertension was observed in pregnant female rats and their offspring exposed to doses approximately twice those used for testosterone replacement therapy. risk summary testosterone gel, 1.62% is not indicated for use in women. infertility testis disorder, testicular atrophy, and oligospermia have been identified during use of androgel 1.62% [see adverse reactions (6.1, 6.2)] . during treatment with large doses of exogenous androgens, including testosterone gel, 1.62%, spermatogenesis may be suppressed through feedback inhibition of the hypothalamic-pituitary-testicular axis [see warnings and precautions (5.8)] . reduced fertility is observed in some men taking testosterone replacement therapy. testicular atrophy, subfertility, and infertility have also been reported in men who abuse anabolic androgenic steroids [see drug abuse and dependence (9.2)] . with either type of use, the impact on fertility may be irreversible. the safety and effectiveness of testosterone gel, 1.62% in pediatric patients less than 18 years old has not been established. improper use may result in acceleration of bone age and premature closure of epiphyses. there have not been sufficient numbers of geriatric patients involved in controlled clinical studies utilizing testosterone gel, 1.62% to determine whether efficacy in those over 65 years of age differs from younger subjects. of the 234 patients enrolled in the clinical trial utilizing testosterone gel, 1.62%, 21 were over 65 years of age. additionally, there is insufficient long-term safety data in geriatric patients to assess the potentially increased risks of cardiovascular disease and prostate cancer. geriatric patients treated with androgens may also be at risk for worsening of signs and symptoms of bph. no studies were conducted involving patients with renal impairment. no studies were conducted in patients with hepatic impairment. testosterone gel, 1.62% contains testosterone, a schedule iii controlled substance in the controlled substances act. drug abuse is intentional non-therapeutic use of a drug, even once, for its rewarding psychological and physiological effects. abuse and misuse of testosterone are seen in male and female adults and adolescents. testosterone, often in combination with other anabolic androgenic steroids (aas), and not obtained by prescription through a pharmacy, may be abused by athletes and bodybuilders. there have been reports of misuse by men taking higher doses of legally obtained testosterone than prescribed and continuing testosterone despite adverse events or against medical advice. abuse-related adverse reactions serious adverse reactions have been reported in individuals who abuse anabolic androgenic steroids and include cardiac arrest, myocardial infarction, hypertrophic cardiomyopathy, congestive heart failure, cerebrovascular accident, hepatotoxicity, and serious psychiatric manifestations, including major depression, mania, paranoia, psychosis, delusions, hallucinations, hostility and aggression. the following adverse reactions have also been reported in men: transient ischemic attacks, convulsions, hypomania, irritability, dyslipidemias, testicular atrophy, subfertility, and infertility. the following additional adverse reactions have been reported in women: hirsutism, virilization, deepening of voice, clitoral enlargement, breast atrophy, male-pattern baldness, and menstrual irregularities. the following adverse reactions have been reported in male and female adolescents: premature closure of bony epiphyses with termination of growth, and precocious puberty. because these reactions are reported voluntarily from a population of uncertain size and may include abuse of other agents, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. behaviors associated with addiction continued abuse of testosterone and other anabolic steroids, leading to addiction is characterized by the following behaviors: - taking greater dosages than prescribed - continued drug use despite medical and social problems due to drug use - spending significant time to obtain the drug when supplies of the drug are interrupted - giving a higher priority to drug use than other obligations - having difficulty in discontinuing the drug despite desires and attempts to do so - experiencing withdrawal symptoms upon abrupt discontinuation of use physical dependence is characterized by withdrawal symptoms after abrupt drug discontinuation or a significant dose reduction of a drug. individuals taking supratherapeutic doses of testosterone may experience withdrawal symptoms lasting for weeks or months which include depressed mood, major depression, fatigue, craving, restlessness, irritability, anorexia, insomnia, decreased libido and hypogonadotropic hypogonadism. drug dependence in individuals using approved doses of testosterone for approved indications has not been documented. instructions for use testosterone (tes tos' ter one) gel, 1.62%, ciii for topical use read this instructions for use for testosterone gel, 1.62% before you start using it and each time you get a refill. there may be new information. this leaflet does not take the place of talking to your healthcare provider about your medical condition or treatment. applying testosterone gel, 1.62%: - testosterone gel, 1.62% comes in a pump. - before applying testosterone gel, 1.62% make sure that your shoulders and upper arms are clean, dry, and that there is no broken skin. - testosterone gel, 1.62% is to be applied to the area of your shoulders and upper arms that will be covered by a short sleeve t-shirt (see figure a). do not apply testosterone gel, 1.62% to any other parts of your body such as your stomach area (abdomen), penis, scrotum, chest, armpits (axillae), or knees. (figure a) if you are using testosterone gel, 1.62% pump: - before using a new bottle of testosterone gel, 1.62% for the first time, you will need to remove the cap, and then prime the pump. to prime the testosterone gel, 1.62% pump, slowly push the pump all the way down 3 times, over the sink drain. do not use any testosterone gel, 1.62% that came out while priming. wash it down the sink to avoid accidental exposure to others. your testosterone gel, 1.62% pump is now ready to use. - remove the cap from the pump. then, put the spout opening at the top of the pump where the medicine comes out over the palm of your hand and slowly push the pump all the way down. apply testosterone gel, 1.62% to the application site. you may also apply testosterone gel, 1.62% directly to the application site. your healthcare provider will tell you the number of times to press the pump for each dose. - wash your hands with soap and water right away. how should i store testosterone gel, 1.62%? - store testosterone gel, 1.62% at room temperature between 68ºf to 77ºf (20ºc to 25ºc). - when it is time to throw away the pump, safely throw away used testosterone gel, 1.62% in household trash. be careful to prevent accidental exposure of children or pets. - keep testosterone gel, 1.62% away from fire. keep testosterone gel, 1.62% and all medicines out of the reach of children. this instructions for use has been approved by the u.s. food and drug administration. revised 10/2019 ifu112-00

アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

laboratorios calier s.a. - luteinizing hormone (lhp); follicle stimulating hormone (fshp); luteinizing hormone (lhp); follicle stimulating hormone (fshp) - powder and solvent for solution for injection - 50/50 international unit(s)/millilitre - gonadotropins - cattle - hormone

イギリス - 英語 - VMD (Veterinary Medicines Directorate)

icpbio (uk) ltd - ovine pituitary follicle stimulating hormone -

ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - lutropin alfa, rch 75 [iu] - powder for injection - 75 iu - active: lutropin alfa, rch 75 [iu] excipient: dibasic sodium phosphate dihydrate methionine monobasic sodium phosphate monohydrate phosphoric acid polysorbate 20 sodium hydroxide sucrose water for injection - luveris in association with a recombinant follicle stimulating hormone (fsh) preparation is recommended for the stimulation of follicular development in women with severe lh and fsh deficiency.

ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

pharmaco (nz) ltd - menotrophin 75 [iu] equivalent to 75 iu fsh & 75 iu lh - powder for injection with diluent - 75 iu - active: menotrophin 75 [iu] equivalent to 75 iu fsh & 75 iu lh excipient: hydrochloric acid lactose monohydrate polysorbate 20 sodium hydroxide hydrochloric acid sodium chloride water for injection - menopur is indicated for the treatment of infertility in anovulation, including polycystic ovarian disease (pcod), in women who have been unresponsive to treatment with clomiphene citrate.

ウガンダ - 英語 - National Drug Authority

bharat serums & vaccines ltd. - recombinant - human follicle stimulating hormone (r-hfsh) - parenteral ordinary pre-filled syringes - 150 i.u/1ml

ウガンダ - 英語 - National Drug Authority

bharat serums & vaccines ltd. - recombinant - human follicle stimulating hormone (r-hfsh) - parenteral ordinary dry vials - 1200iu/vial (multidose)

欧州連合 - 英語 - EMA (European Medicines Agency)

gedeon richter plc. - follitropin alfa - anovulation - sex hormones and modulators of the genital system, - in adult women:anovulation (including polycystic ovarian disease, pcod) in women who have been unresponsive to treatment with clomiphene citrate;stimulation of multifollicular development in patients undergoing superovulation for assisted reproductive technologies (art) such as in vitro fertilisation (ivf), gamete intra-fallopian transfer (gift) and zygote intra-fallopian transfer (zift);follitropin alfa in association with a luteinising hormone (lh) preparation is recommended for the stimulation of follicular development in women with severe lh and fsh deficiency. in clinical trials these patients were defined by an endogenous serum lh level < 1.2 iu/l.in adult men:follitropin alfa is indicated for the stimulation of spermatogenesis in men who have congenital or acquired hypogonadotrophic hypogonadism with concomitant human chorionic gonadotrophin (hcg) therapy.

欧州連合 - 英語 - EMA (European Medicines Agency)

n.v. organon - corifollitropin alfa - reproductive techniques, assisted; ovulation induction; investigative techniques - sex hormones and modulators of the genital system, - controlled ovarian stimulation (cos) in combination with a gnrh antagonist for the development of multiple follicles in women participating in an assisted reproductive technology (art) program.elonva is indicated for the treatment of adolescent males (14 to less than 18 years and older) with hypogonadotropic hypogonadism, in combination with human chorionic gonadotropin (hcg).

オーストラリア - 英語 - APVMA (Australian Pesticides and Veterinary Medicines Authority)

jurox pty limited - fsh-ovine - endocrine system - cattle | goat | sheep | beef | billy | bos indicus | bos taurus | bovine | buck | buffalo | bull | bullock | calf | capra hircus - stimulate ovulation | promote ovulation | superovulation